Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Adenocarcinoma of the Breast
Interventions: DRUG: epirubicin, cyclophosphamide, Paclitaxel,
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Amgen|Pfizer